# | Date | Analyst Firm | Upside/Downside | Price Target Change | Rating Change | Current Rating |
---|
HC Wainwright & Co. analyst Ed Arce reiterates Terns Pharma (NASDAQ:TERN) with a Neutral and maintains $5.5 price target.
JMP Securities analyst Silvan Tuerkcan reiterates Terns Pharma (NASDAQ:TERN) with a Market Outperform and maintains $15 pric...
Ability to dose TERN-701 without regard to food represents a key potential differentiator within the allosteric BCR-ABL inhibit...
UBS analyst Eliana Merle maintains Terns Pharma (NASDAQ:TERN) with a Buy and lowers the price target from $19 to $18.
JMP Securities analyst Silvan Tuerkcan maintains Terns Pharma (NASDAQ:TERN) with a Outperform and lowers the price target fr...
BMO Capital analyst Etzer Darout maintains Terns Pharma (NASDAQ:TERN) with a Outperform and raises the price target from $18...
HC Wainwright & Co. analyst Ed Arce reiterates Terns Pharma (NASDAQ:TERN) with a Neutral and maintains $5.5 price target.
Terns Pharma (NASDAQ:TERN) reported quarterly losses of $(0.29) per share which met the analyst consensus estimate. This is unc...